A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
10.12997/jla.2022.11.3.250
- Author:
Kyuho KIM
1
;
Sung Hee CHOI
Author Information
1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
- Publication Type:Review
- From:Journal of Lipid and Atherosclerosis
2022;11(3):250-261
- CountryRepublic of Korea
- Language:English
-
Abstract:
There are unmet needs for pharmacologic agents beyond current medications, such as statins, to effectively lower low-density lipoprotein cholesterol levels to target goals, especially in patients with very high or extremely high risk. Pharmacological targeting of mRNA represents an emerging, innovative approach with the potential to expand upon current therapies. In RNA-targeted therapeutics, a novel approach is the use of chemically modified oligonucleotides to inhibit the production of target proteins at their sites of gene coding. There are two main classes of RNA-targeted therapeutics: single-stranded antisense oligonucleotides (ASOs) and double-stranded small inhibiting RNAs. ASOs are synthetic molecules with a length of 15–30 nucleotides that are designed specifically to bind to a target mRNA in a sequence-specific manner. Using these agents to inhibit the translation of key regulatory proteins, such as apolipoprotein CIII, apolipoprotein(a), and angiopoietinlike protein 3, has demonstrated treatment efficacy for dyslipidemia. Many cardiovascular outcome trials with ASOs are ongoing. As clinicians, we must carefully monitor the longterm safety and efficacy of this new modality through large clinical trials in the future.
